The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

The tumor microenvironment (TME) is a complex and ever-changing “rogue organ”
composed of its own blood supply, lymphatic and nervous systems, stroma, immune cells …

Chemotherapy has historically been the mainstay of cancer treatment, but our
understanding of what drives a successful therapeutic response remains limited. The …

The success of immunotherapy in oncology underscores the vital role of the immune system
in cancer development. Regulatory T cells (Tregs) maintain a fine balance between …

Naturally occurring CD4+ regulatory T cells (Tregs), which specifically express the
transcription factor FoxP3 in the nucleus and CD25 and CTLA-4 on the cell surface, are a …

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

Current immunotherapies yield remarkable clinical outcomes by boosting the power of host
immunity in cancer cell elimination and viral clearance. However, after prolonged antigen …

Foxp3‐expressing regulatory T (Treg) cells, which are indispensable for preventing
autoimmunity, also suppress effective tumor immunity. Treg cells abundantly infiltrate into …

T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain
immune homeostasis and inhibit immune responses in various diseases, including cancer …

Abstract Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell
cycle and are required for the initiation and progression of various malignancies …